Rama Kumari Badyal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rama Kumari Badyal has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Rajesh Prasad Jayaswal
Department of Medical Laboratory Science, University Institute of Allied Health Sciences Chandigarh University Mohali Punjab India
9 shared publications Amarjit S Kataria
Department of Pathology, Government Medical College, Amritsar, Punjab, India
2 shared publications- Mehak Garg
Department of Nutrition & Dietetics, University Institute of Allied Health Sciences, Chandigarh University, Mohali, India
2 shared publications Shailendra Thapliyal
Uttaranchal Institute of Technology, Uttaranchal University, Dehradun, India
2 shared publicationsAmarjit Singh Kataria
Government Medical College
1 shared publication- Anuj Kumar Rana
Department of Biotechnology, School of Applied and Life Sciences, Uttaranchal University, Dehradun, India
1 shared publication
Latest Publications
- 29 October 2026
- Published by Springer Nature in Current Nutrition Reports
- Vol. 15 (1) , 91
Digital Malnutrition Screening in Older Adults: Translating Technological Detection Into Equitable Nutrition-Care Pathways
- 29 October 2026
- Published by Springer Nature in Current Nutrition Reports
- Vol. 15 (1) , 91
Digital Malnutrition Screening in Older Adults: Translating Technological Detection Into Equitable Nutrition-Care Pathways
- 25 July 2026
- Published by Wiley in Australasian Journal of Ultrasound in Medicine
- Vol. 29 (3) , e70046
Beyond Reprocessing Compliance: Implementing Ultrasound Transducer Hygiene Guidelines Through Audit, Adaptation and Patient Safety
- 25 July 2026
- Published by Wiley in Australasian Journal of Ultrasound in Medicine
- Vol. 29 (3) , e70046
Beyond Reprocessing Compliance: Implementing Ultrasound Transducer Hygiene Guidelines Through Audit, Adaptation and Patient Safety
- 26 June 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 217 (3)
Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy
This correspondence comments on LeVee et al.'s real-world study of neoadjuvant chemo-immunotherapy in early-stage triple-negative breast cancer. We highlight diabetes as a potentially modifiable host-state factor influencing pathologic complete response and propose a metabolic immunotherapy-readiness framework integrating glycaemic control, treatment delivery, endocrine monitoring, and equity-focused implementation. This perspective aims to support globally applicable strategies for improving chemo-immunotherapy effectiveness and access.
- 26 June 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 217 (3)
Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy
This correspondence comments on LeVee et al.'s real-world study of neoadjuvant chemo-immunotherapy in early-stage triple-negative breast cancer. We highlight diabetes as a potentially modifiable host-state factor influencing pathologic complete response and propose a metabolic immunotherapy-readiness framework integrating glycaemic control, treatment delivery, endocrine monitoring, and equity-focused implementation. This perspective aims to support globally applicable strategies for improving chemo-immunotherapy effectiveness and access.
- 26 June 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 217 (3) , 65
Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer
DPYD genotyping before capecitabine therapy represents a clinically actionable pharmacogenomic strategy to reduce avoidable fluoropyrimidine-related toxicity in metastatic breast cancer. Commenting on the cost-effectiveness analysis by Chiddarwar, Blaes and Kuntz, this correspondence supports the authors’ findings while extending the discussion from economic value to implementation readiness. We propose that DPYD testing should be evaluated through a globally transferable framework incorporating ancestry-aware variant coverage, rapid turnaround pathways, genotype-linked dose decision support, budget-impact assessment and real-world toxicity surveillance. Such an approach may help translate cost-effective pharmacogenomics into equitable, operationally feasible breast cancer care across diverse health systems.
- 26 June 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 217 (3) , 65
Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer
DPYD genotyping before capecitabine therapy represents a clinically actionable pharmacogenomic strategy to reduce avoidable fluoropyrimidine-related toxicity in metastatic breast cancer. Commenting on the cost-effectiveness analysis by Chiddarwar, Blaes and Kuntz, this correspondence supports the authors’ findings while extending the discussion from economic value to implementation readiness. We propose that DPYD testing should be evaluated through a globally transferable framework incorporating ancestry-aware variant coverage, rapid turnaround pathways, genotype-linked dose decision support, budget-impact assessment and real-world toxicity surveillance. Such an approach may help translate cost-effective pharmacogenomics into equitable, operationally feasible breast cancer care across diverse health systems.
- 2 June 2026
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 80 (8) , 864-865
From dietary-pattern discovery to precision nutrition equity in type 2 diabetes
- 2 June 2026
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 80 (8) , 864-865
From dietary-pattern discovery to precision nutrition equity in type 2 diabetes
- Open Access
- 18 February 2022
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 16 (1) , 1-4
Aggressive (deep) angiomyxoma of the vulva: a case report
Background: Aggressive angiomyxoma of the vulva is a benign, slow-growing tumor originating from myxoid cells of connective tissue. The tumor is known for multiple local recurrences with a low tendency to metastasize. Only around 350 cases have been documented in the scientific literature so far. Case presentation: We report a case of a 40-year-old North Indian, unmarried woman with a swelling on the left labium majora for 7 years, along with surface ulceration over the mass. Local examination showed a well-circumscribed, 8 × 8 cm pedunculated mass arising from the left labium majora with an overlying ulcer measuring 6 cm × 4 cm. After taking informed written consent, wide local excision of the mass and surrounding margins was done under anesthesia. Histopathology was suggestive of aggressive angiomyxoma. Immunohistochemistry was done, which was positive for estrogen and progesterone receptors. Her postoperative recovery was uneventful. The patient was given three doses of gonadotropin-releasing hormone agonist (injection, leuprolide 3.75 mg) once a month. No recurrence has been reported so far on follow-up visits for 1 year. Conclusion: Aggressive angiomyxoma is one of the differential diagnoses for vulvovaginal growth in a female. As the tumor is well known for local recurrences, correct diagnosis and appropriate management using a multidisciplinary approach are crucial to managing such patients.
- 18 February 2022
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 16 (1) , 1-4
Open AccessAggressive (deep) angiomyxoma of the vulva: a case report
Background: Aggressive angiomyxoma of the vulva is a benign, slow-growing tumor originating from myxoid cells of connective tissue. The tumor is known for multiple local recurrences with a low tendency to metastasize. Only around 350 cases have been documented in the scientific literature so far. Case presentation: We report a case of a 40-year-old North Indian, unmarried woman with a swelling on the left labium majora for 7 years, along with surface ulceration over the mass. Local examination showed a well-circumscribed, 8 × 8 cm pedunculated mass arising from the left labium majora with an overlying ulcer measuring 6 cm × 4 cm. After taking informed written consent, wide local excision of the mass and surrounding margins was done under anesthesia. Histopathology was suggestive of aggressive angiomyxoma. Immunohistochemistry was done, which was positive for estrogen and progesterone receptors. Her postoperative recovery was uneventful. The patient was given three doses of gonadotropin-releasing hormone agonist (injection, leuprolide 3.75 mg) once a month. No recurrence has been reported so far on follow-up visits for 1 year. Conclusion: Aggressive angiomyxoma is one of the differential diagnoses for vulvovaginal growth in a female. As the tumor is well known for local recurrences, correct diagnosis and appropriate management using a multidisciplinary approach are crucial to managing such patients.